287 related articles for article (PubMed ID: 29570299)
21. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate.
Fan M; Yang D; Liang X; Ao J; Li Z; Wang H; Shi B
Biomed Pharmacother; 2015 Mar; 70():268-73. PubMed ID: 25776511
[TBL] [Abstract][Full Text] [Related]
22. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
23. Short Drug-Light Intervals Improve Liposomal Chemophototherapy in Mice Bearing MIA PaCa-2 Xenografts.
Luo D; Carter KA; Geng J; He X; Lovell JF
Mol Pharm; 2018 Sep; 15(9):3682-3689. PubMed ID: 29608312
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
25. Angiopep-2-conjugated poly(ethylene glycol)-
Lu F; Pang Z; Zhao J; Jin K; Li H; Pang Q; Zhang L; Pang Z
Int J Nanomedicine; 2017; 12():2117-2127. PubMed ID: 28356732
[TBL] [Abstract][Full Text] [Related]
26. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.
Jia D; Yang Y; Yuan F; Fan Q; Wang F; Huang Y; Song H; Hu P; Wang R; Li G; Liu R; Li J
Int J Pharm; 2020 Aug; 586():119541. PubMed ID: 32544521
[TBL] [Abstract][Full Text] [Related]
27. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract][Full Text] [Related]
28. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
29. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
30. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
32. Self-crosslinkable and intracellularly decrosslinkable biodegradable micellar nanoparticles: A robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy.
Zou Y; Fang Y; Meng H; Meng F; Deng C; Zhang J; Zhong Z
J Control Release; 2016 Dec; 244(Pt B):326-335. PubMed ID: 27245309
[TBL] [Abstract][Full Text] [Related]
33. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
Arai T; Benny O; Joki T; Menon LG; Machluf M; Abe T; Carroll RS; Black PM
Anticancer Res; 2010 Apr; 30(4):1057-64. PubMed ID: 20530409
[TBL] [Abstract][Full Text] [Related]
34. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
[TBL] [Abstract][Full Text] [Related]
35. Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system.
Chen YC; Chiang CF; Chen LF; Liang PC; Hsieh WY; Lin WL
Biomaterials; 2014 Apr; 35(13):4066-81. PubMed ID: 24513319
[TBL] [Abstract][Full Text] [Related]
36. Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic Ovarian Carcinoma.
Guo L; Zhang Y; Yang Z; Peng H; Wei R; Wang C; Feng M
ACS Nano; 2019 Feb; 13(2):1078-1096. PubMed ID: 30608136
[TBL] [Abstract][Full Text] [Related]
37. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
38. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo.
Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C
J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610
[TBL] [Abstract][Full Text] [Related]
39. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
40. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
